M May1, C Gilfrich2, P Spachmann3, O Maurer2, M K Dombrowski3, H M Fritsche3, M Wöhr4, S Brookman-May5, T Karl2, M Schostak6, M Burger3, S Lebentrau7. 1. Urologische Klinik, St. Elisabeth-Klinikum Straubing, St. Elisabeth-Str. 23, 94315, Straubing, Deutschland. matthias.may@klinikum-straubing.de. 2. Urologische Klinik, St. Elisabeth-Klinikum Straubing, St. Elisabeth-Str. 23, 94315, Straubing, Deutschland. 3. Urologische Klinik, Universitätsklinikum Regensburg, Caritas-Krankenhaus St. Josef, Regensburg, Deutschland. 4. Urologische Klinik, RoMed Klinikum Rosenheim, Rosenheim, Deutschland. 5. Urologische Klinik, Ludwig-Maximilians-Universität München, München, Deutschland. 6. Urologische Klinik, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland. 7. Urologische Klinik, Ruppiner Kliniken Neuruppin, Neuruppin, Deutschland.
Abstract
BACKGROUND: According to the results of a recent meta-analysis, cancer-specific mortality of prostate cancer (PCA) patients is enhanced by 24 % in case of a positive smoking history with a dose-dependent impact of smoking. Until now it is unknown whether this information actually reaches the patients and how extensively an informational discussion about this topic is pursued by physicians. OBJECTIVE: Three study hypotheses were defined: (1) the knowledge of PCA patients about the potential relationship between tumor progression and cigarette consumption is low, (2) only in rare cases has a clear statement been provided by treating physicians including the explicit advice to stop smoking, and (3) there was a direct association between tumor stage and the extent of cigarette consumption. MATERIALS AND METHODS: A questionnaire comprising 23 items was developed and validated with 25 uro-oncological patients prior to study start. Between September 2013 and December 2014 a total of 124 PCA patients (median age 65 years) from two urology departments were included in this questionnaire-based survey. RESULTS: The study population comprised 43 % (n = 54), 39 % (n = 48), and 18 % (n = 22) nonsmokers, former smokers and active smokers, respectively. Active and former smokers differed insignificantly in the number of pack-years only (24.8 vs. 23.7 years, p = 0.995). Of the patients, 56 % regarded an influence of cigarette consumption on the PCA-specific prognosis as possible. However, because a significant (p < 0.001) number of patients wrongly suspected smoking to be causative for PCA development, their knowledge about PCA prognosis is supposedly not based on adequate knowledge. Two of 22 active smokers (9.1 %), 5 of 48 former smokers (10.4 %), and 2 of 54 nonsmokers (3.7 %) had an informational discussion with their urologist about the association of cigarette consumption and PCA-related prognosis (a further 9.1, 4.2 and 3.7 %, respectively, received this information solely from other medical specialties). Only 1 of 22 active smokers (4.5 %) was offered medical aids for smoking cessation by the general practitioner; none of the patients received such support by an urologist. There was no association between a positive smoking history or number of pack-years and PCA tumor stage. CONCLUSIONS: Education of PCA patients about the relationship between cigarette consumption and cancer-related prognosis is currently inadequate. Following the latest findings on this topic, urologists should pursue informational discussions with their patients, thereby strengthening their position as the primary contact person for decision making in PCA management.
BACKGROUND: According to the results of a recent meta-analysis, cancer-specific mortality of prostate cancer (PCA) patients is enhanced by 24 % in case of a positive smoking history with a dose-dependent impact of smoking. Until now it is unknown whether this information actually reaches the patients and how extensively an informational discussion about this topic is pursued by physicians. OBJECTIVE: Three study hypotheses were defined: (1) the knowledge of PCA patients about the potential relationship between tumor progression and cigarette consumption is low, (2) only in rare cases has a clear statement been provided by treating physicians including the explicit advice to stop smoking, and (3) there was a direct association between tumor stage and the extent of cigarette consumption. MATERIALS AND METHODS: A questionnaire comprising 23 items was developed and validated with 25 uro-oncological patients prior to study start. Between September 2013 and December 2014 a total of 124 PCA patients (median age 65 years) from two urology departments were included in this questionnaire-based survey. RESULTS: The study population comprised 43 % (n = 54), 39 % (n = 48), and 18 % (n = 22) nonsmokers, former smokers and active smokers, respectively. Active and former smokers differed insignificantly in the number of pack-years only (24.8 vs. 23.7 years, p = 0.995). Of the patients, 56 % regarded an influence of cigarette consumption on the PCA-specific prognosis as possible. However, because a significant (p < 0.001) number of patients wrongly suspected smoking to be causative for PCA development, their knowledge about PCA prognosis is supposedly not based on adequate knowledge. Two of 22 active smokers (9.1 %), 5 of 48 former smokers (10.4 %), and 2 of 54 nonsmokers (3.7 %) had an informational discussion with their urologist about the association of cigarette consumption and PCA-related prognosis (a further 9.1, 4.2 and 3.7 %, respectively, received this information solely from other medical specialties). Only 1 of 22 active smokers (4.5 %) was offered medical aids for smoking cessation by the general practitioner; none of the patients received such support by an urologist. There was no association between a positive smoking history or number of pack-years and PCA tumor stage. CONCLUSIONS: Education of PCA patients about the relationship between cigarette consumption and cancer-related prognosis is currently inadequate. Following the latest findings on this topic, urologists should pursue informational discussions with their patients, thereby strengthening their position as the primary contact person for decision making in PCA management.
Authors: Daniel F Zapata; Lauren E Howard; William J Aronson; Christopher J Kane; Martha K Terris; Christopher L Amling; Matthew R Cooperberg; Stephen J Freedland Journal: Int J Urol Date: 2015-04-14 Impact factor: 3.369
Authors: Corinne E Joshu; Alison M Mondul; Cari L Meinhold; Elizabeth B Humphreys; Misop Han; Patrick C Walsh; Elizabeth A Platz Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Daniel M Moreira; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Paolo Boffetta; Stephen J Freedland Journal: Cancer Date: 2013-10-11 Impact factor: 6.860
Authors: Malte Rieken; Shahrokh F Shariat; Luis A Kluth; Harun Fajkovic; Michael Rink; Pierre I Karakiewicz; Christian Seitz; Alberto Briganti; Morgan Rouprêt; Wolfgang Loidl; Quoc-Dien Trinh; Alexander Bachmann; Gholamreza Pourmand Journal: Eur Urol Date: 2015-06-03 Impact factor: 20.096
Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet Journal: Eur Urol Date: 2013-11-12 Impact factor: 20.096
Authors: Andrew Rundle; Kathryn M Neckerman; Daniel Sheehan; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki Journal: Cancer Causes Control Date: 2012-12-08 Impact factor: 2.506
Authors: Christian Gilfrich; Odilo Maurer; Philipp J Spachmann; Mirja K Dombrowski; Maximilian Burger; Matthias May Journal: World J Urol Date: 2018-08-11 Impact factor: 4.226